Skip to main content
SpringerLink
Log in

Plasminogen activator system modulates invasivecapacity and proliferation in prostatic tumor cells

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

The malignant phenotype of prostatic tumor cells correlates with the expression of both uPA and itscell-membrane receptor (uPAR); however, there is little information concerning the role of cell-bound uPAin matrix degradation and invasion. Our results suggest that cell-associated uPA plays a key role in regulat-ingthe amount of plasmin present at the surface of prostatic carcinoma (PRCA) cells and show that differ-entialproduction of uPA corresponds with the capacity to bind and activate plasminogen. In addition, weprovide direct evidence that both uPA secretion and the presence of uPA-uPAR complexes characterize theinvasive phenotype of PRCA cells and suggest the existence of several pathways by which tumor cells acquireplasmin activity. LNCaP cells (which do not produce uPA but express uPAR) may activate plasmin throughexogenous uPA. In vivo, the source of uPA may be infiltrating macrophages and/or fibroblasts as observedin several other systems. PAI-1 accumulation in the conditioned medium (CM) limits plasmin action to thepericellular microenvironment. Our results indicate that MMP-9 and MMP-2 are also activated by plasmingenerated by cell-bound but not by soluble, extracellular uPA. Plasmin activation and triggering of the pro-teolyticcascade involved in Matrigel invasion is blocked by antibodies against uPA (especially by anti- A-chainof uPA which interacts with uPAR) and by PA inhibitors such as p-aminobenzamidine which mayregulate levels of cell-bound uPA. uPA may also regulate growth in PRCA cells. Indeed, antibodies againstuPA A-chain (and also p-aminobenzamidine treatment) interfere with the ATF domain and inhibit cell growthin uPA-producing PC3 and DU145 prostate cancer cell lines, whereas exogenous uPA (HMW-uPA with ATF)induces growth of LNCaP prostate tumor cell line. These data support the hypothesis that in prostatic can-cerpatients at risk of progression, uPA/plasmin blockade may be of therapeutic value by blocking both growthof the primary tumor and dissemination of metastatic cells. ©Kluwer Academic Publishers

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Danø K, Andreasen PA, Grøndahl-Hansen J, et al.1985, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, 139-266.

    Google Scholar 

  2. Danø K, Grøndahl-Hansen J, Eriksen J, et al. 1993, The receptor for uPA: stromal cell involvement in extracellular proteolysis during cancer invasion. In: Bond JS and Barrett AJ, eds. Proteolysis and Protein Turnover. London: Portland Press, pp. 239-45.

    Google Scholar 

  3. Blasi F, Vassalli JD and Danø K, 1987, Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors. J Cell Biol, 104, 801-4.

    Google Scholar 

  4. Saskela O and Rifkin DB, 1988, Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 4, 93-126.

    Google Scholar 

  5. Ellis V, Pyke C, Erikson J, et al.1992, The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci USA 667, 3113-27.

    Google Scholar 

  6. Schmitt M, Janicke F, Moniva N, et al. 1992, Tumor associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem 373, 611-22.

    Google Scholar 

  7. Blasi F, 1993, Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioassays 15, 105-11.

    Google Scholar 

  8. Plow EF, Freaney DE, Plescia J and Miles LA, 1986, The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 103, 2411-18.

    Google Scholar 

  9. Stephens RW, Pollanen J, Tapiovaara H, et al. 1989, Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 108, 1987-95.

    Google Scholar 

  10. Pollanen J, Stephens RW and Vaheri A, 1991, Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res, 57, 273-328.

    Google Scholar 

  11. Kobayashi H, Hidezaku O, Sugimura M, et al. 1992, Inhibition of in vitroovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res, 52, 3610-14.

    Google Scholar 

  12. Kobayashi H, Shinohara H, Takeuchi K, et al. 1994, Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res, 54, 844-9.

    Google Scholar 

  13. Ossowski L, Russo-Payne H and Wilson EL, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse model. Cancer Res, 51, 274-81.

    Google Scholar 

  14. Crowley CW, Cohen RL, Lucas BK, et al. 1993, Prevention of metastasis by inhibition of the urokinase receptor. Cell Biol 90, 5021-5.

    Google Scholar 

  15. Miles LA and Plow EF, 1985, Binding and activation of plasminogen on the platelet surface. J Biol Chem, 260, 4303-11.

    Google Scholar 

  16. Achbarou A, Kaiser S, Tremblay G, et al. 1994, Urokinase overexpression results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res, 54, 2372-7.

    Google Scholar 

  17. Ossowski L, 1988, Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell, 52, 321-8.

    Google Scholar 

  18. Stoppelli MP, Tacchetti C, Cubellis MV, et al. 1986, Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell, 45, 675-84.

    Google Scholar 

  19. Lahito M and Keski-Oja J, 1989, Growth factors in regulation of pericellular proteolysis: a review. Cancer Res, 49, 2533-53.

    Google Scholar 

  20. Ploug M, Rønne E, Behrendt N, et al. 1991, Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosil-phosphatidyl inositol. J Biol Chem, 266, 1926-33.

    Google Scholar 

  21. Stephens RW, Leung KC, Pollanen J, et al.1987, Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Meth, 105, 245-51.

    Google Scholar 

  22. Hearing VJ, Law LW, Appella E and Blasi F, 1988, Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res, 48, 1270-8.

    Google Scholar 

  23. Imamura H, Takao S and Aikou T, 1994, A modified invasion-3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay for quantitating tumor cell invasion. Cancer Res, 54, 3620-4.

    Google Scholar 

  24. Reich E, 1978, Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: Berlin RD, Hermann H, Lepow IH and Tanzer JM, eds. Molecular Basis of Biological Degradative Processes. Academic Press, New York, pp. 155-69.

    Google Scholar 

  25. Baker MS, Bleakley P, Woodrow GC and Doe WF, 1990, Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res, 50, 4676-84.

    Google Scholar 

  26. Koslowski JM, Fidler IJ and Campbell D, 1984, Metastatic behaviour of human tumor cell lines in the nude mouse. Cancer Res, 44, 3322-9.

    Google Scholar 

  27. Hoosein NM, Boyd DD, Hollas WJ, et al. 1991, Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun, 3, 255-64.

    Google Scholar 

  28. Hall SW, Humphries JE and Gonias SL, 1991, Inhibition of cell surface receptor bound plasmin by α2-antiplasmin and α2-macroglobulin. J Biol Chem, 266, 12329-36.

    Google Scholar 

  29. Pyke C, Kristiansen P, Ralfkiaer E, et al. 1991, Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at the invasive foci in human colon adenocarcinomas. Am J Pathol 138, 1059-67.

    Google Scholar 

  30. Pyke C, Graezm N, Ralfkiaer E, et al. 1993, Receptor for urokinase is present in tumor associated macrophages in ductal breast carcinomas. Cancer Res, 53, 1911-15.

    Google Scholar 

  31. Billstrom A, Lecander I, Dagnaes-Hensen F, et al. 1995, Differential expression of uPA in an aggressive (DU145) and a nonaggressive (1013L) human prostate xenograft. Prostate 26, 94-104.

    Google Scholar 

  32. Lyon PB, See WA, Xu Y and Cohen MB, 1995, Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 27, 179-86.

    Google Scholar 

  33. Wilson MJ and Sinha AA, 1993, Plasminogen activator and metalloproteinase activities of DU145, PC3 and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Cell Mol Biol Res, 39, 751-60.

    Google Scholar 

  34. Blasi F, 1988, Surface receptors for urokinase plasminogen activator. Fibrinol, 2, 73-84.

    Google Scholar 

  35. Nielsen LS, Grøndahl-Hansen J, Andreasen PA, et al. 1986, Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activators and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay, 7, 209-28.

    Google Scholar 

  36. Andreasen PA, Nielsen LS, Kristiansen P, et al. 1986, Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem, 261, 7644-51.

    Google Scholar 

  37. Stephens RW, Leung KC, Pollanen J, et al.1987, Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Meth, 105, 245-51.

    Google Scholar 

  38. Wun TC and Reich E, 1987, An inhibitor of plasminogen activation from human placenta. J Biol Chem, 262, 3646-53.

    Google Scholar 

  39. Pollanen J, Saksela O, Salonen EM, et al. 1987, Distinct localizations of urokinase-type plasminogen activator and its inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol, 104, 1085-96.

    Google Scholar 

  40. Pollanen J, Edman K, Nielsen LS, et al.1988, Ultrastructural localization of plasma membrane-associated urokinase type plasminogen activator of focal contacts. J Cell Biol, 106, 87-95.

    Google Scholar 

  41. Herbert CA and Baker JB, 1988, Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: co-localization of cell surface urokinase with vinculin. J Cell Biol, 106, 1241-7.

    Google Scholar 

  42. Casslén B, Gustavsson B and Astedt B, 1991, Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur J Cancer, 27, 1445-8.

    Google Scholar 

  43. Festuccia C, Bologna M, Vicentini C, et al. 1996, Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer, 69, 386-93.

    Google Scholar 

  44. Hamdy FC, Cottam DW, Rees RC and Williams JL, 1994, Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer, 69, 177-82.

    Google Scholar 

  45. Festuccia C, Guerra F, D'Ascenzo S, et al. 1998, In vitroregulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer, 75, 418-31.

    Google Scholar 

  46. Bologna M, Festuccia C, Muzi P, et al.1989, Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63, 1714-20.

    Google Scholar 

  47. Jarrad DF, Blitz BF, Smith RC, et al.1994, Effect of EGF on prostate cancer cell line PC3 growth and invasion. Prostate 24, 46-53.

    Google Scholar 

  48. Billstrom A, Hartley-Asp B, Lecander I, Batra S and Astedt B, 1995, The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostatic tumor in SCID mice. Int J Cancer, 61, 542-7.

    Google Scholar 

  49. Festuccia C, Vicentini C, Firma N, et al. 1995, Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res, 7, 131-8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy

    Claudio Festuccia, Vincenza Dolo, Fulvio Guerra, Stefania Violini, Paola Muzi, Antonio Pavan & Mauro Bologna

Authors
  1. Claudio Festuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincenza Dolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fulvio Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefania Violini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Muzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antonio Pavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mauro Bologna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Festuccia, C., Dolo, V., Guerra, F. et al. Plasminogen activator system modulates invasivecapacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16, 513–528 (1998). https://doi.org/10.1023/A:1006590217724

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006590217724

Search

Navigation